A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

NCT07204418 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Xanomeline/ Trospium Chloride

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company